Clazakizumab
Humanized | |
---|---|
Target | IL6 |
Clinical data | |
Other names | ALD518, BMS-945429 |
Routes of administration | infusion |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6426H9972N1724O2032S42 |
Molar mass | 145239.02 g·mol−1 |
Clazakizumab (formerly ALD518 and BMS-945429), an
dose-response effect.[2]
See also
- Tocilizumab (Actemra) an anti-IL-6 receptor mAb
- Anti-IL-6, other anti-interleukin-6 agents
References
- ISBN 9783527329373. Retrieved January 23, 2017.
- S2CID 3644962.